Mestinon


Also found in: Encyclopedia.

pyridostigmine bromide

Mestinon, Mestinon-SR (CA), Mestinon Timespan, Regonol

Pharmacologic class: Anticholinesterase

Therapeutic class: Muscle stimulant, antimyasthenic

Pregnancy risk category C

Action

Prevents acetylcholine destruction, resulting in stronger contractions of muscles weakened by myasthenia gravis or curare-like neuromuscular blockers

Availability

Injection: 5 mg/ml

Syrup: 60 mg/5 ml

Tablets: 60 mg

Tablets (extended-release): 180 mg

Indications and dosages

Myasthenia gravis

Adults: 600 mg P.O. given over 24 hours, with doses spaced for maximum symptom relief. For myasthenic crisis, 2 mg or 1/30 of oral dose I.M. or very slow I.V. q 2 to 3 hours.

Postoperative reversal of nondepolarizing neuromuscular blockers

Adults: 10 to 20 mg slow I.V. injection (range is 0.1 to 0.25 mg/kg) with or immediately after 0.6 to 1.2 mg atropine sulfate I.V.

Dosage adjustment

• Renal impairment
• Seizure disorders

Off-label uses

• Myasthenia gravis in children
• Constipation in patients with Parkinson's disease
• Nerve agent prophylaxis

Contraindications

• Hypersensitivity to drug or bromides
• Mechanical intestinal or urinary tract obstruction

Precautions

Use cautiously in:
• seizure disorders, bronchial asthma, coronary occlusion, arrhythmias, bradycardia, hyperthyroidism, peptic ulcer, vagotonia, cholinergic crisis
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

Administration

Don't exceed I.V. injection rate of 1 mg/minute.

Don't give concurrently with other anticholinesterase drugs.
• Have atropine available for use in emergencies.

Adverse reactions

CNS: headache, dysarthria, dysphoria, drowsiness, dizziness, headache, syncope, loss of consciousness, seizures

CV: decreased cardiac output leading to hypotension, bradycardia, nodal rhythm, atrioventricular block, cardiac arrest, arrhythmias

EENT: diplopia, lacrimation, miosis, spasm of accommodation, conjunctival hyperemia

GI: nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, flatulence dysphagia, increased salivation

GU: urinary frequency, urgency, or incontinence

Musculoskeletal: muscle weakness, fasciculations, and cramps; joint pain

Respiratory: increased pharyngeal and tracheobronchial secretions, dyspnea, central respiratory paralysis, respiratory muscle paralysis, laryngospasm, bronchospasm, bronchiolar constriction

Skin: diaphoresis, flushing, rash, urticaria

Other: thrombophlebitis at I.V. site, cholinergic crisis, anaphylaxis

Interactions

Drug-drug.Aminoglycosides: potentiation of neuromuscular blockade

Anesthetics (general and local), antiarrhythmics: decreased anticholinesterase effects

Atropine, belladonna derivatives: suppression of parasympathomimetic GI symptoms (leaving only fasciculations and voluntary muscle paralysis as signs of anticholinesterase overdose)

Corticosteroids: decreased anticholinesterase effects; after corticosteroid withdrawal, increased anticholinesterase effects

Ganglionic blockers (such as mecamy-lamine): increased anticholinesterase effects

Magnesium: antagonism of beneficial anticholinesterase effects

Nondepolarizing neuromuscular blockers (atropine, pancuronium, tubocurarine): antagonism of neuromuscular blockade and reversal of muscle relaxation after surgery (with parenteral pyridostigmine)

Other anticholinesterase drugs: in patients with myasthenia gravis, symptoms of anticholinesterase overdose that mimic underdose, causing patient's condition to worsen

Succinylcholine: increased and prolonged neuromuscular blockade (including respiratory depression)

Patient monitoring

• Assess patient's response to each dose.
• Monitor vital signs, ECG, and cardiovascular and respiratory status.

Assess for signs and symptoms of overdose, which indicate cholinergic crisis.

Patient teaching

• If patient is using syrup, advise him to pour it over ice.
• Instruct patient using extended-release tablets not to crush them.

Teach patient to recognize and promptly report signs and symptoms of overdose, including muscle fasciculations, sweating, excessive salivation, and constricted pupils.
• Tell patient drug may cause headache and muscle cramps. Encourage him to discuss activity recommendations and pain management with prescriber.
• Advise patient to monitor and report his response to ongoing therapy so that optimal dosage can be determined.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Mestinon

a trademark for a neuromuscular blocking agent (pyridostigmine bromide).

Mestinon

An oral agent used to manage myasthenia gravis.

Adverse effects
• Muscarinic—Nausea, vomiting, diarrhoea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis, diaphoresis; reversed with atropine.
• Nicotinic—Muscle cramps, fasciculation and weakness.

Mestinon®

Pyridostigmine, see there.

Pyridostigmine bromide (Mestinon)

An anticholinesterase drug used in treating myasthenia gravis.
Mentioned in: Myasthenia Gravis
References in periodicals archive ?
She was taking mestinon, an acetylcholinesterase inhibitor, for control of her MG symptoms, which precluded the use of anticholinergic medications.
Specialist pharmaceutical company Impax Laboratories (NasdaqGS:IPXL) disclosed on Thursday that it has received US Food and Drug Administration (FDA) approval for generic Mestinon Timespan Tablets (pyridostigmine bromide extended release), 180 mg for the treatment of myasthenia gravis.
Meda's sales of Mestinon (treatment of myasthenia gravis, an autoimmune disease) amounted to SEK 129 million (137).
Since the beginning, she had been taking Mestinon every five hours or so and therefore was able to work at a local nursing facility doing patient care.
In the cours eof those 8 days, she was introduced to another, and more durable, anticholinesterase agent, called, Mestinon, and an effective dosage (one 60-milligram tablet every four hours) was determined.
In April Impax received approval for a generic version of Mestinon (pyridostigmine bromide) 60-mg tablets, which are prescribed for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder primarily characterized by muscle weakness and rapid muscle fatigue.
Usually an anticholinesterase medication is the first-line treatment for patients with MG; Mestinon [R] (pyridostigmine) is usually the drug of choice.
has been given clearance for generic Mestinon (pyridostigmine bromide) 60-mg tablets.
Efudex, Cesamet, Diastat AcuDial, Kinerase, Mestinon, Zelapar, Migranal, Bedoyecta, Dermatix and Bisocard are trademarks or registered trademarks of Valeant Pharmaceuticals International or its related companies.
Efudex, Diastat AcuDial, Kinerase, Mestinon, Zelapar, Migranal, Bedoyecta, Dermatix and Bisocard are trademarks or registered trademarks of Valeant Pharmaceuticals International or its related companies.
Sales of Mestinon, Bisocard and Dermatix increased in the third quarter, which were offset by a decrease in vision care products due to the divestment of the company's ophthalmic business in the Netherlands earlier in 2007.
Sales of several promoted products were higher, including Solcoseryl, Bisocard and Mestinon.